HOME > TRENDS

    TRENDS

    Chugai Led in Research Grants Payment in FY2013; Grants Fell Among Major Drug Makers

    November 5, 2014
    As the disclosures of drug makers’ FY2013 payments to medical institutions have run their course, Jiho looked into their spending on research grants, which have received increasing scrutiny in the wake of the clinical trial scandal involving Novartis Pharma’s blood…

    To read the full story

    Related Article

    TRENDS

    COLUMN

    A Conversation with James Feliciano: Navigating the Complexities of the Japanese Pharmaceutical Industry
    By Philip Carrigan

    In a recent conversation with James Feliciano, former president of AbbVie Japan, we delved into the intricacies of leadership in the Japanese pharmaceutical industry. Feliciano, a seasoned industry veteran, shared valuable insights into his experiences, challenges, and successes.Navigating the Abbott…

    Chuikyo Debate on Off-Year Drug Price Revisions

    MHLW Proposes Setting Product Scope for Off-Year Revisions by Category
    By Ken Yoshino

    The Ministry of Health, Labor and Welfare (MHLW) on December 18 presented a proposal to define the scope of products…

    Drug Approval & Reimbursement in 2024

    Kisunla Gets Reimbursement Listing with Daily NHI Price of 8,560 Yen
    By Ken Yoshino

    Eli Lilly’s Kisunla (donanemab) will join the Japanese reimbursement list on November 20, with a health ministry panel giving the…

    COMMENTARY

    Battle over Off-Year Price Revision Now Heading for Political Settlement
    By Yoshinori Sagehashi

    Will an “off-year” drug price revision happen in April 2025 or not? Over the last week, expectations have been up…

    MHLW Panel on Generic Industry Structure

    MHLW Panel Draws Up Plans for Generic Industry Shakeup in Final Report

    A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…

    MHLW Panel on Pharmaceutical Regulations

    Japan Set to Push Central IRBs for Clinical Trials, Avoid Customary All-Case PMS

    A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…

    Chuikyo on FY2024 Reimbursement Reform

    Chuikyo OKs Outline of FY2024 Drug Pricing Reform; No Unprofitability Re-Pricing for 7%-Plus Price Gap

    Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…

    MHLW Expert Panel on Comprehensive Policies

    Expert Panel Broadly OKs Draft Report on Pharma Policies, Further Deliberations by Other Forums
    By Yoshinori Sagehashi

    The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…

    Jiho Survey: FY2022 Drug Price Revision

    Authorized Generics Likely Speeding Up G1/G2 Price Cuts for Off-Patent Brands: Jiho Tally

    Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…

    FY2022 Drug Pricing Reform

    MHLW Unveils New List Prices for FY2022 Revision, 18 Off-Patent APIs Face Early “G1” Cuts

    Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…